Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 241Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 88Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Multiple Myeloma 64Leukemia 58Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 35Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Neoplasm Metastasis 25Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 20Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × Prednisone × Clear all
NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡